Hualing Medicine (2552.HK) Achieves Historic Profit Breakthrough in 2025, Gross Profit Up 125% Year-over-Year, Product Sales Nearly Double Year-over-Year

NightAirdropper · 2026-03-27T02:45:04+00:00

Hualing Medicine-B(2552.HK)2025 achieved significant growth, with a pre-tax profit of 1.1064 billion yuan, a 125% year-over-year increase in gross profit. Product sales surged by 91%, while sales expenses were significantly reduced. Huatangning® continues to maintain medical insurance pricing, with good progress in clinical research. In the future, it will submit new indication IND applications and explore combination therapy options.

NightAirdropper

2026-03-27 02:45:04

Abstract generation in progress

Gelonghui March 27 | HuaLing Medicine-B (2552.HK) announced its full-year 2025 results. The company achieved a historic breakthrough in profitability, with pre-tax profit reaching 1.1064 billion RMB, and commercialized business profit amounting to 114.9 million RMB. During the period, gross profit increased by 125% year-over-year to 280.4 million RMB, with gross profit margin rising by 8.2 percentage points to 56.9%. As of the end of 2025, cash reserves were approximately 1.0923 billion RMB, providing a solid foundation for the company’s ongoing development.

The company has fully ramped up commercialization efforts, with product sales volume increasing by 91% year-over-year to 4.011 million boxes, and sales revenue up 93% to 492.9 million RMB; sales expenses accounted for 33.6% of revenue, a significant decrease of 26.3% compared to 2024. Notably, Huatangning® prescriptions in domestic secondary and tertiary hospitals have grown significantly, benefiting over 500,000 patients through more than 3,000 hospitals, community health centers, pharmacies, and online channels. Huatangning® also successfully renewed its original price in the new medical insurance catalog, maintaining the same price for 2026-2027, with clinical and innovative value further recognized.

In addition, HuaLing Medicine has made breakthrough progress in multiple clinical studies, with new indications and innovative therapies continuously expanding. The company plans to submit an IND application for Dapagliflozin for MODY-2 patients in 2026; after completing the study in 2026, it will explore new opportunities to submit IND applications for Dapagliflozin for diabetes prevention in China and the Asia-Pacific region; future plans also include initiating clinical research on innovative therapies for mild cognitive impairment. Meanwhile, the company is exploring combination therapies involving Dapagliflozin with GLP-1 receptor agonists and SGLT-2 inhibitors.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.